Concepedia

Author

R. Corre

Centre Hospitalier Universitaire de RennesORCID

Also Known As

Corre, R., Corre, Romain, F Barlesi, R CORRE, R Corre, R. Corre, Romain Corre, Rozenn Corre

173

Publications

9.9K

Citations

24

H-Index

53

Concepts

All Affiliations

Centre Hospitalier Universitaire de RennesInsermHôpital Intercommunal de CréteilHôpital PontchaillouSorbonne Université
RC

About

R. Corre is an author at Centre Hospitalier Universitaire de Rennes specializing in medicine, radiation oncology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

16

22

7.3K

2

Health Sciences

11

12

735

3

Public Health

1

1

213

4

Allergy

1

1

14

5

Cell Biology

1

1

150

R. Corre

×

45

Publications

9.5K

Citations

23

H-Index

YearCitations

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais,

The Lancet Oncology

2012

5.5K

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

Gérard Zalcman, Julien Mazières, J. Margery,

The Lancet

2015

965

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

Arnaud Scherpereel, Julien Mazières, Laurent Greillier,

The Lancet Oncology

2019

451

Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study

R. Corre, Laurent Greillier, H. Le Caer,

Journal of Clinical Oncology

2016

401

Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac Output

Sophie Dupuis‐Girod, Isabelle Ginon, Jean‐Christophe Saurin,

JAMA

2012

378

Association of<i>EGFR</i>L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

Niki Karachaliou, Clara Mayo-de las Casas, Cristina Queralt,

JAMA Oncology

2015

234

Pulmonary Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia

Vincent Cottin, Thierry Chinet, A. Lavolé,

Medicine

2007

213

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

Martin Reck, Michael Schenker, Ki Hyeong Lee,

European Journal of Cancer

2019

212

Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non–Small-Cell Lung Cancers Reveal Major Discordances

Florian Cabillic, Audrey Gros, Frédéric Dugay,

Journal of Thoracic Oncology

2014

150

Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis

Matteo Giaj Levra, François-Emery Cotté, R. Corre,

Lung Cancer

2019

123

Page 1